FDA panel backs Pfizer's maternal RSV vaccine
A panel of advisors to the US Food and Drug Administration (FDA) votes to support Pfizer’s experimental maternal respiratory syncytial virus (RSV) vaccine for protection of infants, writes news agency Reuters.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.